title: Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms?
abstract: Alpha-lipoic acid (ALA) is widely used as an antioxidant for the treatment of diabetes and its complications; however, the pro-oxidant potential of ALA has recently been reported. This study was designed to investigate whether ALA supplementation could have pro-oxidant effects on cardiac tissues in normal and diabetic rats. Diabetes was induced by a single dose of streptozotocin (STZ; 55 mg/kg (intraperitoneal). Diabetic and normal rats were treated with ALA (100 mg kg(-1) day(-1)) for 45 days. ALA supplementation resulted in oxidative protein damage as evident by significant reduction in the cardiac levels of protein thiol in ALA-treated normal rats (P < 0.01) together with a significant elevation (P < 0.001) in the plasma levels of advanced oxidation protein products in ALA-treated normal rats and in ALA + STZ-diabetic rats compared with the normal control rats. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has emerged as the major source of superoxide anion and enhanced oxidative damage in heart failure. ALA supplementation increased the myocardial immunoreactivity of p47phox subunit of NADPH oxidase in both normal nondiabetic and diabetic rats reflecting its pro-oxidant effect. Data showed that ALA supplementation failed to prevent cardiac complications in diabetic rats and led to cardiac toxicity in normal rats as indicated by pathological changes (cellular infiltration, fibrosis, and degeneration) and by the elevation of serum cardiac biomarkers compared with normal controls. The pro-oxidant effects of ALA suggest that careful selection of appropriate doses of ALA in reactive oxygen species-related diseases are critical.
authors.affiliation: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11495, Kingdom of Saudi Arabia.
authors.forename: Nouf M
authors.initials: NM
authors.lastname: Al-Rasheed
authors.forename: Nawal M
authors.initials: NM
authors.lastname: Al-Rasheed
authors.forename: Hala A
authors.initials: HA
authors.lastname: Attia
authors.forename: Iman H
authors.initials: IH
authors.lastname: Hasan
authors.forename: Maha
authors.initials: M
authors.lastname: Al-Amin
authors.forename: Hanaa
authors.initials: H
authors.lastname: Al-Ajmi
authors.forename: Raeesa A
authors.initials: RA
authors.lastname: Mohamad
mesh_terms: D000818:Animals; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000819:agonists / Q000097:blood; D006333:Heart Failure / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D019255:NADPH Oxidases / Q000378:metabolism*; D016877:Oxidants / Q000009:adverse effects*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000819:agonists* / Q000378:metabolism; D013311:Streptozocin; D008063:Thioctic Acid / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood; D019210:Troponin I / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D017127:Glycation End Products, Advanced; D016877:Oxidants; D017382:Reactive Oxygen Species; D014280:Triglycerides; D019210:Troponin I; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D008315:Malondialdehyde; D013311:Streptozocin; D008063:Thioctic Acid; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1